Related Experiment Video
Updated: Jun 26, 2026
09:28
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
Trends in biopharmaceutical IPOS: 1996-2005
David R Williams1, Carlton C Young
1Department of Management, Walker College of Business, Appalachian State University, USA.
Journal of Health Care Finance
|January 30, 2009
Summary
Biopharmaceutical firms experienced a 20.9% average stock price increase on their first day of public offering (IPO). However, long-term survival saw a lower 7.7% average stock price increase, with many firms merging or being acquired.
Area of Science:
- Biopharmaceutical industry
- Financial markets
- Corporate finance
Background:
- Initial Public Offerings (IPOs) are critical for biopharmaceutical firms' growth.
- Understanding post-IPO financial performance is essential for investors and the industry.
- The period 1996-2005 saw significant activity in biopharmaceutical IPOs.
Purpose of the Study:
- To analyze the stock market reaction to biopharmaceutical IPOs.
- To examine the long-term financial performance of these firms.
- To investigate the survival rates and reasons for delisting.
Main Methods:
- Analysis of stock price performance for biopharmaceutical IPOs from 1996-2005.
- Tracking of stock prices from IPO day to year-end 2005.
- Examination of delisting reasons, including mergers and acquisitions.
Main Results:
- Average first-day stock price increase was 20.9%.
- Average stock price increase for surviving firms by year-end 2005 was 7.7%.
- 69% of firms were still trading by year-end 2005; most delisted firms were acquired or merged.
Conclusions:
- Biopharmaceutical IPOs show strong initial market interest but more moderate long-term gains.
- Mergers and acquisitions are common outcomes for delisted biopharmaceutical companies.
- Venture capital played a significant role, with investors owning 47.4% of stock pre-IPO.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...